In Vitro Diagnostics Business Outlook, Volume 3, Issue 6 - Glucose Testing

20 Dec 2024

Categories:

In Vitro Diagnostics Business Outlook is a bimonthly publication with six issues annually.

In Vitro Diagnostics Business Outlook offers information and data that you cannot get anywhere else, including:

Market data and forecasts (growth rates, market size, market share, etc.) to identify growth opportunities
A comprehensive view of the IVD market with test categories covered and company briefs
M&A activities, selected partnerships & collaborations, partnership deals, and more
Industry & region watch to help tailor strategies
Analysis of news and events and reporting on news not easily available

Table of Contents

Market Analysis: IVD Glucose Testing
- Overview of IVD Glucose Testing
Market Outlook
- Regional Market
- Company Briefs
  - Abbott Diagnostics
  - Dexcom
  - Roche
Executive News Briefing
- Briefs
  - Agilent Reorganizes Business Units
  - Natera Co-Founder Named R&D Leader of the Year
  - QIAGEN Moves QIAstat-Dx to Drive Growth
  - OraSure Receives Funding
  - AmplifiDx Captures Additional Funding
  - 52North Closes $6 Million in Funding
Financial Highlights: Abbott Laboratories, QIAGEN
- Abbott Continues Steady Performance in 2024; 9M Sales Increase 3.7%
- QIAGEN Reports Strong Performance in Q3 2024; Raises Guidance
Diagnostic Market Mergers, Acquisitions and Partnership Deals
- Partnerships and Collaborations
- Mergers and Acquisitions
Industry Watch
- Industry Watch COVID-19/Flu Update
Region Watch
- Vietnam
Broad-based Company Announcements
- Announcements
  - Roche Receives FDA Expanded Approval
  - Foundation Medicine Received FDA Companion Diagnostic Approval
  - Deepull Receives FDA Breakthrough Device Designation
  - bioMérieux Snags Clearance for Tropical Fever Panel
  - Roche Receives CE Mark for New Cobas Systems 2.0
  - Agilent Received Certification for Companion Diagnostic

Attachments